Precision Oncology Infrastructure

    RisxAI™

    Ask anything about cancer and chronic-disease management — diagnostics, biomarkers, treatments, and care. Clear, supportive answers in plain language.

    3 free questions left

    Ask a question, or start with one of these

    RisxAI provides general educational information, not medical advice. Consult your healthcare provider for personal decisions.

    Measured evidence

    Method & full evidence
    $490.3M–$658.8M
    Oncology NGS spending we measured · Original Medicare Part B, CY2024, Part B allowed payment
    $572.2M
    held outside that estimate under unlisted code 81479method and indication cannot be identified — reported, not added in
    $1.33B → $3.06B
    named oral NSCLC agents, Part D, 2020 → 2024 · gross drug cost, rebates not netted — never summed with Part B

    The widely repeated $2.5B market figure is a claim with no primary source we have captured; our measurement is 19.6%–26.4% of it. Every figure we publish carries its source, fetch date and price basis — and Part B is never summed with Part D.

    CMS, Original Medicare Part B claims (data.cms.gov), via the digest-verified RISX store · fetched 2026-08-15

    RISX Science

    Precision oncology starts before the prescription.

    RisX Science deploys the diagnostic infrastructure, contracting architecture, and pathway intelligence that ensures complete biomarker profiles are available before treatment decisions are made — for health plans, clinicians, and biopharma partners.

    About RISX